Antibody-directed therapy: past, present, and future.
Antibody-based therapy, which is the administration of polyclonal, hyperimmune, or monoclonal antibodies, has emerged as an important therapeutic approach in a wide variety of diseases. Polyclonal intravenous immunoglobulin became available in the early 1980s and supplanted intramuscular IgG in the treatment of antibody-deficiency diseases. During the last 2 decades, intravenous immunoglobulin has shown potent immunomodulatory and anti-inflammatory effects in many diseases. Whether these effects are mediated through specific antibody or Fc-receptor interactions is unclear. This review examines some of the current and future prospects for antibody-based therapy.
Gelfand
E W
EW
Division of Cell Biology, Department of Pediatrics, National Jewish Medical and Research Center, Denver, CO 80206, USA.
D000906:Antibodies / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001327:Autoimmune Diseases / Q000628:therapy; D006801:Humans; D006967:Hypersensitivity / Q000628:therapy; D007154:Immune System Diseases / Q000628:therapy*; D007074:Immunoglobulin G / Q000627:therapeutic use; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007153:Immunologic Deficiency Syndromes / Q000628:therapy; D007249:Inflammation / Q000628:therapy
D000906:Antibodies; D000911:Antibodies, Monoclonal; D007074:Immunoglobulin G; D016756:Immunoglobulins, Intravenous